These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 28452111)

  • 1. Epigenetic dysregulation of ID4 predicts disease progression and treatment outcome in myeloid malignancies.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Zhang W; Yang L; Yan Y; Lin J; Qian J
    J Cell Mol Med; 2017 Aug; 21(8):1468-1481. PubMed ID: 28452111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome.
    Wang H; Wang XQ; Xu XP; Lin GW
    Leuk Res; 2010 May; 34(5):598-604. PubMed ID: 19853913
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Zhou JD; Li XX; Zhang TJ; Xu ZJ; Zhang ZH; Gu Y; Wen XM; Zhang W; Ji RB; Deng ZQ; Lin J; Qian J
    Aging (Albany NY); 2019 May; 11(10):3376-3391. PubMed ID: 31147526
    [No Abstract]   [Full Text] [Related]  

  • 4. [Methylation status of id4 gene promoter in patients with chronic myeloid leukemia].
    Wang XR; Kang HY; Cen J; Li YH; Wang LL; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1402-4. PubMed ID: 21176338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic landscape of the TERT promoter: a potential biomarker for high risk AML/MDS.
    Zhao X; Tian X; Kajigaya S; Cantilena CR; Strickland S; Savani BN; Mohan S; Feng X; Keyvanfar K; Dunavin N; Townsley DM; Dumitriu B; Battiwalla M; Rezvani K; Young NS; Barrett AJ; Ito S
    Br J Haematol; 2016 Nov; 175(3):427-439. PubMed ID: 27433923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.
    Kang H; Wang X; Gao L; Cen J; Li M; Wang W; Wang N; Li Y; Wang L; Yu L
    Eur J Med Res; 2015 Feb; 20(1):16. PubMed ID: 25889027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential methylation pattern of ID4, SFRP1, and SHP1 between acute myeloid leukemia and chronic myeloid leukemia.
    Uhm KO; Lee ES; Lee YM; Park JS; Kim SJ; Kim BS; Kim HS; Park SH
    J Korean Med Sci; 2009 Jun; 24(3):493-7. PubMed ID: 19543515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylation-independent CHFR expression is a potential biomarker affecting prognosis in acute myeloid leukemia.
    Zhou JD; Zhang TJ; Li XX; Ma JC; Guo H; Wen XM; Yao DM; Zhang W; Lin J; Qian J
    J Cell Physiol; 2018 Jun; 233(6):4707-4714. PubMed ID: 29115660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the correlation between Chinese medical syndrome types and ID4 gene promoter methylation in human acute myeloid leukemia].
    Liu F; Xu RR
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):471-3. PubMed ID: 22803425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of SRY-box containing gene family member
    Zhou JD; Wang YX; Zhang TJ; Li XX; Gu Y; Zhang W; Ma JC; Lin J; Qian J
    Clin Epigenetics; 2018; 10():92. PubMed ID: 30002740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
    [No Abstract]   [Full Text] [Related]  

  • 12. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
    Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
    Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression pattern and prognostic implication of SALL4 gene in myeloid leukemias: a case-control study.
    Farawela HM; Zawam HM; Al-Wakeel HA; El-Nagdy MH; El-Refaey FA; Abdel-Rahman HA
    Scand J Clin Lab Invest; 2019; 79(1-2):65-70. PubMed ID: 30638095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemia].
    Yang H; Zhu HY; Jiang MM; Wang QS; Han XP; Huang WR; Jing Y; Wang SH; Zhang SS; Mei JH; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):121-5. PubMed ID: 23484704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.
    Grövdal M; Karimi M; Khan R; Aggerholm A; Antunovic P; Astermark J; Bernell P; Engström LM; Kjeldsen L; Linder O; Nilsson L; Olsson A; Holm MS; Tangen JM; Wallvik J; Oberg G; Hokland P; Jacobsen SE; Porwit A; Hellström-Lindberg E
    Br J Haematol; 2010 Aug; 150(3):293-302. PubMed ID: 20497178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypermethylation of ITGBL1 is associated with poor prognosis in acute myeloid leukemia.
    Lian XY; Ma JC; Zhou JD; Zhang TJ; Wu DH; Deng ZQ; Zhang ZH; Li XX; He PF; Yan Y; Lin J; Qian J
    J Cell Physiol; 2019 Jun; 234(6):9438-9446. PubMed ID: 30317626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [ID4 promoter methylation in acute myeloid leukemia].
    Xu RR; Liu F; Cui X; Zhang XW; Wang Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):582-4. PubMed ID: 21729527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
    Zhou JD; Lin J; Zhang TJ; Ma JC; Li XX; Wen XM; Guo H; Xu ZJ; Deng ZQ; Zhang W; Qian J
    J Cell Physiol; 2018 Mar; 233(3):2444-2450. PubMed ID: 28776669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Down-regulation of transcription factor PU.1 via abnormal epigenetic modification in chronic myeloid leukemia].
    Yang H; Yan JS; Tao R; Hao SG; Liang H; Ma LY
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):169-75. PubMed ID: 22780968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.